Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Visainn - you describe my own position exactly!
The very best of good luck to you and to all holders!
Ben4 - you’re a top quality poster- thanks for your valued input.
Do you think there’s any mileage in the idea that Boris gets to break the Big News first on Monday evening and that AS will hold back any RNS until Tuesday morning ?
If so, and IF Boris gets the script right, the big SP rise would come on Tuesday.... after only a more modest rise on Monday?
Surely time again for AS to submit to yet another fierce grilling by the boy Giles?
Thank you, Sir Al - we have lift off!
It’s been a long road, holding shares here for several years - and holding my breath for what seems like most of them - but this is the news that gets the company established firmly on the scientific radar , with SO much more to come, especially in the world of oncology.
The sky really is the limit now!
Avacta rules!
Hants - a helpful post, thank you.
I think £500 million would amount (roughly) to a mere £2 or so a share.
Wouldn’t even look at an offer as weak as that.
Needs to be £10+ to make it interesting- otherwise, hold, hold , hold !!!
IMHO
Hurst - a fascinating and very clear read.
The best explanation of the PCR/LFT differences and consequences I’ve read to date.
Thank you.
More good work, Unprecedented - very helpful, thanks!
Thanks for sharing, ben4 - a high quality post!
You and Unprecedented, among a few others, are raising the standards on this BB.
Encouraging .
Always a pleasure to see you posting, Ophidian.
Don’t hesitate to drop by more often - and ignore the utter morons!
A great summary - and a great company!
Thanks.
If I briefly had any slight uncertainties, this RNS has removed them altogether.
IMHO this message, whilst obviously it cannot amount to a guarantee, seems to me to solidify Avacta’s position to the point where I feel that major success is now almost a racing certainty.
Been here since 2013, way before Covid hit the world, and I could not be happier with my investment.
Keep up the stellar work, Avacta.
A world beating company is emerging.....
A good post, Unprecedented.
Keep up the good work and lucid appraisals!
Thanks.
Thanks, Hants for a balanced, sensible appraisal.
Makes a lot of sense - and hope you are right!
Thanks, Muck - good post.
I’ve been hoping to read of progress in Avacta’s link with Daewoong, but each time I find one of Daewoong’s updates I can never find any specific mention of Affimers or Avacta.
I presume that Affimers must be involved , but it’s disappointing that Daewoong never seem openly to acknowledge Avacta’s input.
What’s your view? Is it that the reported work being done is actually separate from the work that they are doing with Avacta, or just that Daewoong want to hog the glory?
The neutralising treatment, when officially approved, will be a HUGE step forward in overcoming the virus - and, equally importantly, in overcoming the natural fears we all have of the adverse effects of the virus in individual patients.
It would be a great time to hear more about the role of Affimers in Daewoong’s work.
Thanks, Unprecedented.
Well researched, well put together - and encouraging!
Wonderful news in today’s RNS!
THIS is the reason I invested here in 2013 and it is encouraging that this step has been reached on schedule.
My guess is that the immediate impact on the share price might be modest, as so much attention has become focused on Covid.
But, if successful, the long term SP uplift from the cancer therapy aspect of the business will dwarf the uplift from the Covid element.
My gut feeling is that massive success awaits on both major fronts in 2021.
Thanks, PL75 - a well made out case, which has the significant advantage of sounding realistic. More than just possible. Fingers crossed you’re on the money!
Arnold Palmer - thanks for your comments. Much appreciated
I fully accept your thoughts about Cytiva’s input with the strip and thank you for clarifying that. A useful point.
PS Do you play as well as your handle implies?!
The dust is very slowly settling after the latest RNS/interview.
The share price has taken a kicking.
The RNS was gently positive, aimed at reassuring investors that progress is being made and all will be well.
But, investor expectations had become very high and there was nothing of sufficiently powerful, immediate impact in the RNS that could possibly satisfy those high expectations.
Unsurprisingly, as expectations had not been managed, investor disappointment showed itself in a large sell off.
The perception was of further delay and the suspicion grew that successful tests might never be produced.
My very amateur view - which people might well disagree with, is this:
Cytiva turned out to be a very unsatisfactory partner and caused many months of delay whilst achieving very little. They put a successful outcome back by that period.
Saliva samples have been found by the whole industry to be extremely difficult to utilise in LFT’s. Anterior nasal samples are a good alternative and seem to offer very promising results. Presumably, a saliva version will follow later if successful.
Perhaps the plug should have been pulled earlier on Cytiva - but we don’t know enough of the surrounding circumstances (eg the contractual position) etc to say that with certainty.
BBI, having replaced Cytiva, seem to have moved with tremendous efficiency since then to produce a workable U.K. sovereign test which has a realistic chance of succeeding - with potentially excellent S/S and reliability, and with the potential to identify asymptomatic cases.
It is likely to gain accreditation and be vastly more accurate than the inferior Innova test which the government, in desperation to show its readiness to embrace the new technology, has unfortunately bought in vast numbers. The likes of Professor Deeks and others will soon enough demonstrate the inadequacies - and maybe even dangers - of relying on inadequate tests , and the public will become aware of this....and thus more receptive to a very superior product from Avacta when it arrives ‘soon’ - query, by mid/late December or maybe early January?
The boat has not sailed. The market is unquenchable and will remain large even after mass vaccination has been achieved. To date, no one has been able to give strong reassurance that vaccinated people will not be spreaders of the virus. Testing will be with us for years to come - worldwide.
My own take is that it is a great shame that Cytiva held us back for so long - and that the pitiful government tardiness and bureaucracy in the Condor scheme etc has delayed matters further. Much revenue has been lost.
But - vast revenues remain to be secured.
With a little good fortune and continuing hard work, Avacta will be a huge success on many fronts, whether Covid or cancer therapy related - and in other applications, too.
2021 will, IMHO, DYOR etc etc, turn out to be a first class investment year for holders of Avacta shares